{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,17]],"date-time":"2026-11-17T03:54:50Z","timestamp":1794887690719,"version":"4.9.1"},"reference-count":35,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"6","license":[{"start":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:00:00Z","timestamp":1738886400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,2,7]]},"abstract":"<jats:p>Type 2 diabetes mellitus (T2DM) is an independent risk factor of knee osteoarthritis (KOA). This study was mainly based on data from the Taiwan National Health Insurance Database. Using big data analysis, we showed that glucagon-like peptide-1 receptor agonist (GLP-1RA) treatment is helpful for patients with T2DM who have a lower risk of KOA or total knee replacement (TKR). A total of 35,762 patients with T2DM were included in this study. We divided these patients into 988 patients with T2DM without KOA and 372 patients with T2DM with KOA who received GLP-1RA treatment and those who did not receive GLP-1RA treatment. The patients were matched for sex, age, and inclusion date by 1:1 propensity score, which was included in the control group. Cox proportional hazards analyses were performed to compare KOA risk and TKR rate during a maximum follow-up period of 5 years. There were 1976\/744 patients with T2DM without\/with KOA who received and did not receive GLP-1RA treatment, including 1052\/322 men (53.24\/43.28%) and 924\/422 women (46.76\/56.72%). At the end of follow-up, there were 46\/39 (4.66\/10.48%) patients with T2DM without\/with KOA who received GLP-1RA treatment and underwent KOA\/TKR were lower than those without GLP-1RA treatment 87\/70 (8.81\/18.82%). Cox proportional hazard regression analysis showed a lower rate of KOA\/TKR among patients with GLP-1RA treatment (adjusted hazard ratio [HR]\u2005=\u2005.852; 95% confidence interval [CI]\u2005=\u2005.784\u2013.930, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001\/ adjusted HR\u2005=\u2005.913; 95% CI\u2005=\u2005.885\u2013.977, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005=\u2005.015, respectively). Kaplan\u2013Meier analysis showed that the cumulative risk of KOA\/TKR in patient with\/without GLP-1RA was significantly different (log-rank test, <jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001\/<jats:italic toggle=\"yes\">P<\/jats:italic>\u2005&lt;\u2005.001, respectively). This study aimed to provide clinicians with the option of GLP-1RA as a treatment for patients with T2DM with or without KOA to reduce the risk of KOA or TKR among such patients.<\/jats:p>","DOI":"10.1097\/md.0000000000041243","type":"journal-article","created":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:00:08Z","timestamp":1739217608000},"page":"e41243","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Glucagon-like peptide-1 receptor agonists therapy to attenuate the risk of knee osteoarthritis and total knee replacement in type 2 diabetes mellitus: A nation-wide population-based cohort study"],"prefix":"10.1097","volume":"104","author":[{"ORCID":"https:\/\/orcid.org\/0009-0006-0246-1793","authenticated-orcid":false,"given":"Chih-Ping","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Zuoying Armed Forces General Hospital, Kaohsiung, Taiwan, ROC"},{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Hsiang","family":"Chung","sequence":"additional","affiliation":[{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC"},{"name":"Taiwanese Injury Prevention and Safety Promotion Association, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chieh-Hua","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sheng-Chiang","family":"Su","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Feng-Chih","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jhih-Syuan","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng-Fei","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Luen","family":"Huang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li-Ju","family":"Ho","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuan-Chan","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Yung","family":"Chang","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"},{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Kaohsiung Armed Forces General Hospital, Kaohsiung, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Shiun","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Chen","family":"Liu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"An-Che","family":"Cheng","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong-Han","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shi-Wen","family":"Kuo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Taipei Tzu Chi Hospital, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chien-Hsing","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang-Hsun","family":"Hsieh","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Jen","family":"Hung","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Division of Endocrinology and Metabolism, Tri-Service General Hospital, School of Medicine, National Defense Medical Center, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Ya","family":"Liu","sequence":"additional","affiliation":[{"name":"BeYoung Research Institute, Taipei, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lan-Yuen","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Sports Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan, ROC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wu-Chien","family":"Chien","sequence":"additional","affiliation":[{"name":"School of Public Health, National Defense Medical Center, Taipei, Taiwan, ROC"},{"name":"Department of Medical Research, Tri-Service General Hospital, National Defense Medical Center, Taipei, Taiwan, ROC."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-20250210","doi-asserted-by":"crossref","first-page":"574","DOI":"10.2337\/dc12-0722","article-title":"Elevated rates of diabetes in pacific islanders and asian subgroups: the Diabetes Study of Northern California (DISTANCE).","volume":"36","author":"Karter","year":"2013","journal-title":"Diabetes Care"},{"key":"R2-20250210","doi-asserted-by":"crossref","first-page":"109119","DOI":"10.1016\/j.diabres.2021.109119","article-title":"IDF Diabetes Atlas: global, regional and country-level diabetes prevalence estimates for 2021 and projections for 2045.","volume":"183","author":"Sun","year":"2022","journal-title":"Diabetes Res Clin Pract"},{"key":"R3-20250210","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1136\/bmj.317.7160.703","article-title":"Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. UK Prospective Diabetes Study Group.","volume":"317","year":"1998","journal-title":"BMJ"},{"key":"R4-20250210","doi-asserted-by":"crossref","first-page":"16044","DOI":"10.1038\/boneres.2016.44","article-title":"Osteoarthritis: toward a comprehensive understanding of pathological mechanism.","volume":"5","author":"Chen","year":"2017","journal-title":"Bone Res"},{"key":"R5-20250210","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1016\/j.berh.2018.10.007","article-title":"Update on the epidemiology, risk factors and disease outcomes of osteoarthritis.","volume":"32","author":"O\u2019Neill","year":"2018","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"R6-20250210","doi-asserted-by":"crossref","first-page":"100587","DOI":"10.1016\/j.eclinm.2020.100587","article-title":"Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies.","volume":"29-30","author":"Cui","year":"2020","journal-title":"EClinicalMedicine"},{"key":"R7-20250210","doi-asserted-by":"crossref","first-page":"403","DOI":"10.2337\/dc12-0924","article-title":"Diabetes is an independent predictor for severe osteoarthritis: results from a longitudinal cohort study.","volume":"36","author":"Schett","year":"2013","journal-title":"Diabetes Care"},{"key":"R8-20250210","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.semarthrit.2019.01.005","article-title":"Type 2 diabetes mellitus and osteoarthritis.","volume":"49","author":"Veronese","year":"2019","journal-title":"Semin Arthritis Rheum"},{"key":"R9-20250210","doi-asserted-by":"crossref","first-page":"212283","DOI":"10.7573\/dic.212283","article-title":"A clinical review of GLP-1 receptor agonists: efficacy and safety in diabetes and beyond.","volume":"4","author":"Prasad-Reddy","year":"2015","journal-title":"Drugs Context"},{"key":"R10-20250210","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1056\/NEJMoa1603827","article-title":"Liraglutide and cardiovascular outcomes in Type 2 Diabetes.","volume":"375","author":"Marso","year":"2016","journal-title":"N Engl J Med"},{"key":"R11-20250210","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.jacbts.2018.09.004","article-title":"The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(-\/-) and LDLr(-\/-) Mice by a mechanism that includes inflammatory pathways.","volume":"3","author":"Rakipovski","year":"2018","journal-title":"JACC Basic Transl Sci"},{"key":"R12-20250210","doi-asserted-by":"crossref","first-page":"1319827","DOI":"10.3389\/fendo.2024.1319827","article-title":"The role of targeting glucose metabolism in chondrocytes in the pathogenesis and therapeutic mechanisms of osteoarthritis: a narrative review.","volume":"15","author":"Pi","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R13-20250210","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.17305\/bb.2024.10426","article-title":"Serum C-reactive protein to albumin ratio as a reliable marker of diabetic neuropathy in type 2 diabetes mellitus.","volume":"24","author":"Aktas","year":"2024","journal-title":"Biomol Biomed"},{"key":"R14-20250210","doi-asserted-by":"crossref","first-page":"5952","DOI":"10.3390\/jcm12185952","article-title":"Association between the prognostic nutritional index and chronic microvascular complications in patients with type 2 Diabetes Mellitus.","volume":"12","author":"Aktas","year":"2023","journal-title":"J Clin Med"},{"key":"R15-20250210","first-page":"9032378","article-title":"SGLT2i and GLP-1RA in cardiometabolic and renal diseases: from glycemic control to adipose tissue inflammation and senescence.","volume":"2021","author":"D\u2019Marco","year":"2021","journal-title":"J Diabetes Res"},{"key":"R16-20250210","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1097\/00005650-199706000-00005","article-title":"International Classification of Diseases, 9th Revision, Clinical Modification codes in discharge abstracts are poor measures of complication occurrence in medical inpatients.","volume":"35","author":"Geraci","year":"1997","journal-title":"Med Care"},{"key":"R17-20250210","doi-asserted-by":"crossref","first-page":"e0191242","DOI":"10.1371\/journal.pone.0191242","article-title":"Combination COX-2 inhibitor and metformin attenuate rate of joint replacement in osteoarthritis with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan.","volume":"13","author":"Lu","year":"2018","journal-title":"PLoS One"},{"key":"R18-20250210","doi-asserted-by":"crossref","first-page":"100831","DOI":"10.1016\/j.imr.2021.100831","article-title":"Traditional Chinese medicine attenuates hospitalization and mortality risks in diabetic patients with carcinoma in situ in Taiwan.","volume":"11","author":"Tsai","year":"2022","journal-title":"Integr Med Res"},{"key":"R19-20250210","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1097\/JCMA.0000000000000743","article-title":"Dipeptidyl peptidase-4 inhibitors attenuates osteoporosis in patients with diabetes: a nationwide, retrospective, matched-cohort study in Taiwan.","volume":"85","author":"Chang","year":"2022","journal-title":"J Chin Med Assoc"},{"key":"R20-20250210","doi-asserted-by":"crossref","first-page":"720477","DOI":"10.3389\/fcell.2021.720477","article-title":"Cell interplay in osteoarthritis.","volume":"9","author":"Li","year":"2021","journal-title":"Front Cell Dev Biol"},{"key":"R21-20250210","doi-asserted-by":"crossref","first-page":"R80","DOI":"10.1186\/ar2713","article-title":"Impaired glucose transporter-1 degradation and increased glucose transport and oxidative stress in response to high glucose in chondrocytes from osteoarthritic versus normal human cartilage.","volume":"11","author":"Rosa","year":"2009","journal-title":"Arthritis Res Ther"},{"key":"R22-20250210","doi-asserted-by":"crossref","first-page":"1393550","DOI":"10.3389\/fendo.2024.1393550","article-title":"The metabolic characteristics and changes of chondrocytes in vivo and in vitro in osteoarthritis.","volume":"15","author":"Adam","year":"2024","journal-title":"Front Endocrinol (Lausanne)"},{"key":"R23-20250210","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.joca.2015.10.017","article-title":"Insulin decreases autophagy and leads to cartilage degradation.","volume":"24","author":"Ribeiro","year":"2016","journal-title":"Osteoarthritis Cartilage"},{"key":"R24-20250210","doi-asserted-by":"crossref","first-page":"14505","DOI":"10.1074\/jbc.M117.802157","article-title":"The nuclear factor-erythroid 2-related factor\/heme oxygenase-1 axis is critical for the inflammatory features of type 2 diabetes-associated osteoarthritis.","volume":"292","author":"Vaamonde-Garcia","year":"2017","journal-title":"J Biol Chem"},{"key":"R25-20250210","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.joca.2018.03.010","article-title":"Type 2 diabetes patients have accelerated cartilage matrix degeneration compared to diabetes free controls: data from the Osteoarthritis Initiative.","volume":"26","author":"Neumann","year":"2018","journal-title":"Osteoarthritis Cartilage"},{"key":"R26-20250210","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1016\/j.cger.2014.08.019","article-title":"Links between osteoarthritis and diabetes: implications for management from a physical activity perspective.","volume":"31","author":"Piva","year":"2015","journal-title":"Clin Geriatr Med"},{"key":"R27-20250210","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1136\/ard.2010.146399","article-title":"Diabetes-induced osteoarthritis: from a new paradigm to a new phenotype.","volume":"70","author":"Berenbaum","year":"2011","journal-title":"Ann Rheum Dis"},{"key":"R28-20250210","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.molmet.2019.09.010","article-title":"Glucagon-like peptide 1 (GLP-1).","volume":"30","author":"Muller","year":"2019","journal-title":"Mol Metab"},{"key":"R29-20250210","doi-asserted-by":"crossref","first-page":"239","DOI":"10.12688\/f1000research.20602.1","article-title":"Recent advances in understanding the role of glucagon-like peptide 1.","volume":"9","author":"Reed","year":"2020","journal-title":"F1000Res"},{"key":"R30-20250210","doi-asserted-by":"crossref","first-page":"e34122","DOI":"10.1097\/MD.0000000000034122","article-title":"Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: a network meta-analysis.","volume":"102","author":"Chen","year":"2023","journal-title":"Medicine (Baltim)"},{"key":"R31-20250210","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1136\/ard.2006.053538","article-title":"Body mass index associated with onset and progression of osteoarthritis of the knee but not of the hip: the Rotterdam Study.","volume":"66","author":"Reijman","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"R32-20250210","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1016\/j.jbspin.2013.09.007","article-title":"Is osteoarthritis a metabolic disease?","volume":"80","author":"Sellam","year":"2013","journal-title":"Joint Bone Spine"},{"key":"R33-20250210","first-page":"27","article-title":"Hypoglycemic agents and potential anti-inflammatory activity.","volume":"9","author":"Kothari","year":"2016","journal-title":"J Inflamm Res"},{"key":"R34-20250210","doi-asserted-by":"crossref","first-page":"14821","DOI":"10.3748\/wjg.v20.i40.14821","article-title":"Effects of glucagon-like peptide-1 receptor agonists on non-alcoholic fatty liver disease and inflammation.","volume":"20","author":"Wang","year":"2014","journal-title":"World J Gastroenterol"},{"key":"R35-20250210","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.jot.2022.02.001","article-title":"Targeting the GLP-1\/GLP-1R axis to treat osteoarthritis: a new opportunity?","volume":"32","author":"Meurot","year":"2022","journal-title":"J Orthop Translat"}],"container-title":["Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041243","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,10]],"date-time":"2025-02-10T20:00:20Z","timestamp":1739217620000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/MD.0000000000041243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2,7]]},"references-count":35,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/md.0000000000041243","relation":{},"ISSN":["1536-5964"],"issn-type":[{"value":"1536-5964","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,2,7]]}}}